In his latest article for Pharmacy Times, Ned Milenkovich, chair of Much’s Health Care group, discussed a halt in developments in the reclassification of marijuana. He explains that while these developments had the potential to initiate significant federal and state legislative changes, the new presidential administration put a pause on the momentum.
